Protein phosphorylation in the regulation of insulin secretion: the use of site-directed inhibitory peptides in electrically permeabilised islets of Langerhans

Efficient gene transfer into murine pancreatic islets using adenovirus vectors

We investigated the efficiency of gene transduction into murine pancreatic islets using the adenovirus (Ad) vector. Western blotting analysis showed that mouse pancreatic islets express coxsackievirus and adenovirus receptor, a receptor for Ad. Nevertheless, gene expression after transduction of the Ad vector in vitro was observed only in the periphery of the islets, probably due to physical obstruction against Ad infection of the cells in the inside of islets. Ca(2+)-free treatment before the Ad vector transduction enhanced transduction efficiency in the islets, but not the cells in the inside of islets. The Ad vector transduction through the celiac artery in vivo and then cultivation of islets in vitro resulted in efficient transduction even in the inside of islets. Thus we propose a new strategy for efficient gene transfer to pancreatic beta-cells.

Threonine phosphorylations induced by RX-871024 and insulin secretagogues in betaTC6-F7 cells

Treatment of the pancreatic beta-cell line betaTC6-F7 with an imidazoline compound, RX-871024, KCl, or tolbutamide resulted in increased threonine phosphorylation of a 220-kDa protein (p220) concurrent with enhanced insulin secretion, which can be partially antagonized by diazoxide, an ATP-sensitive potassium (K(ATP)) channel activator. Although phosphorylation of p220 was regulated by cytoplasmic free calcium concentration ([Ca(2+)](i)), membrane depolarization alone was not sufficient to induce phosphorylation. Phosphorylation of p220 also was not directly mediated by protein kinase A, protein kinase C, or insulin exocytosis. Analysis of subcellular fractions indicated that p220 is a hydrophilic protein localized exclusively in the cytosol. Subsequently, p220 was purified to homogeneity, sequenced, and identified as nonmuscle myosin heavy chain-A (MHC-A). Stimulation of threonine phosphorylation of nonmuscle MHC-A by KCl treatment also resulted in increased phosphorylation of a 40-kDa protein, which was coimmunoprecipitated by antibody to MHC-A. Our results suggest that both nonmuscle MHC-A and the 40-kDa protein may play roles in regulating signal transduction, leading to insulin secretion.

Pseudosubstrate peptide inhibitors of beta-cell protein kinases: altered selectivity after myristoylation

Inhibitors of protein kinases are widely used to study stimulus-response pathways in pancreatic beta-cells. Synthetic peptides modelled on the pseudosubstrate sites of protein kinases, or of their endogenous inhibitor proteins, offer potentially specific inhibitors of individual protein kinases or kinase isoforms. However, the use of these inhibitors in studies of beta-cell physiology has been limited, since such peptide sequences are usually poorly membrane permeant. Myristoylation of these peptides enhances their ability to cross intact plasma membranes and thus inhibit intracellular protein kinases, and this approach is becoming increasingly common in identifying the cellular role(s) of particular protein kinases. In this study, using insulin-secreting beta-cells, we demonstrate that myristoylation alters the specificity of pseudosubstrate peptides such that all myristoylated peptides tested, even those lacking pseudosubstrate domains, acted as protein kinase C (PKC) inhibitors. This effect of myristoylation was limited to the inhibition of PKC, since the specificity of peptide inhibitors towards beta-cell protein kinase A activity was not affected by myristoylation. These results demonstrate that myristoylated pseudosubstrate peptides have value as protein kinase inhibitors in intact beta-cells, but emphasise that studies using them to ascribe role(s) for protein kinases in beta-cells must be interpreted with caution.

Ca(2+)-induced loss of Ca2+/calmodulin-dependent protein kinase II activity in pancreatic beta-cells

Elevations in intracellular Ca2+ in electrically permeabilized islets of Langerhans produced rapid insulin secretory responses from beta-cells, but the Ca(2+)-induced secretion was not maintained and was irrespective of the pattern of administration of elevated Ca2+. Ca(2+)-insensitive beta-cells responded normally to activators of protein kinase C or cAMP-dependent kinase with increased insulin secretion. The loss of secretory responsiveness to Ca2+ was paralleled by a reduction in Ca(2+)-induced protein phosphorylation. This was caused by a reduction in Ca2+/calmodulin-dependent protein kinase II (CaMK II) activity in the desensitized cells, as assessed by measuring the phosphorylation of a CaMK II-specific exogenous substrate, autocamtide-2. The Ca(2+)-induced reductions in kinase activity and protein phosphorylation were not dependent on the activation of Ca(2+)-dependent protein kinases and were not caused by the activation of phosphoprotein phosphatases or of Ca(2+)-activated proteases. The concomitant reductions in CaMK II activity and Ca(2+)-induced insulin secretion suggest that the activation of CaMK II is required for normal insulin secretory responses to increased intracellular Ca2+ concentrations.

Pseudosubstrate inhibition of cyclic AMP-dependent protein kinase in intact pancreatic islets: effects on cyclic AMP-dependent and glucose-dependent insulin secretion

Synthetic peptides derived from the endogenous protein kinase A inhibitor (PKI) offer a specific means of inhibiting cyclic AMP-dependent protein kinase A (PKA), but their use in whole cells is restricted by the plasma membrane. We have now modified PKI sequences by N-terminal myristoylation to enhance their membrane permeability, and have used the myristoylated (myr) peptides to investigate the role of PKA activation in glucose-induced insulin secretion from intact pancreatic beta-cells. The myristoylated PKI peptides, myr PKI14-22 and myrPKI6-22, were effective inhibitors in vitro of PKA activity extracted from rat islets of Langerhans. In experiments using intact islets, myr PKI14-22 caused a concentration-dependent inhibition of insulin secretion in response to the PKA activators dibutyryl cyclic AMP and forskolin, suggesting that it gained access to the cytosolic compartment of intact beta-cells and inhibited PKA in situ. However, these concentrations of myr PKI14-22 did not inhibit insulin secretion in response to glucose suggesting that the activation of PKA is not required for the initiation of glucose-induced insulin secretion.

Signal transduction pathways mediating parathyroid hormone stimulation of bone sialoprotein gene expression in osteoblasts

Bone sialoprotein is a major noncollagenous protein of bone. Parathyroid hormone (PTH) was shown to cause a 2-4-fold increase in the steady-state levels of bone sialoprotein mRNAs within primary cultures of embryonic osteoblasts. The induction could be mimicked by both forskolin and phorbol 12-myristate 13-acetate and was not inhibited by cycloheximide. Transient expression of a approximately 1200-base pair avian 5' bsp promoter/reporter construct demonstrated similar inductions as mRNA levels. Co-transfection of an expression plasmid encoding heat-stable inhibitor of cAMP-dependent protein kinase, a peptide inhibitor of PKA, decreased both the basal and PTH-induced bsp transcription, while co-expression of the catalytic subunit of PKA-induced bsp expression 3-fold. Protein kinase C activation, on the other hand, did not appear to work through its activation of c-fos, since co-transfection of an expression clone for c-fos had no effect. Interestingly, heat-stable inhibitor of cAMP-dependent protein kinase also inhibited the phorbol 12-myristate 13-acetate induction, suggesting that the protein kinase C acts through some form of interaction with the cAMP/PKA pathway. A half-cAMP response element site in the bsp promoter was identified as the cis-acting element that mediated the PTH response by the transient transfections with reporter constructs containing nested deletions of the promoter or a heterologous promoter containing the cAMP response element. In conclusion, these data indicate that PTH stimulation of bsp gene expression is specific to osteoblasts and mediated by changing cellular cAMP/PKA levels. They further suggest that although protein kinase C is capable of stimulating the gene by itself, it plays a minimal role in mediating the PTH induction of bone sialoprotein.

A myristoylated pseudosubstrate peptide inhibitor of protein kinase C: effects on glucose- and carbachol-induced insulin secretion

We have used synthetic pseudosubstrate peptide inhibitors of protein kinase C (PKC) to re-examine the role of conventional isoforms of PKC in the insulin secretory response of intact rat islets of Langerhans to glucose and to the cholinergic agonist carbachol (CCh). One peptide was modified by N-terminal myristoylation (PKC-myr20-28) to allow its use in intact beta-cells. Maximal inhibition of PKC activity in vitro required 10-fold less of this peptide (PKC-myr20-28) than of its non-myristoylated analogue. The maximum inhibitory concentration of PKC-myr20-28 had little effect on islet protein kinase A or Ca2+/calmodulin kinase activities. PKC-myr20-28 (25-100 microM) caused a dose-dependent inhibition of phorbol myristate acetate (PMA)-induced insulin secretion from intact rat islets but non-myristoylated peptides had little effect on the secretory response to PMA. A concentration of PKC-myr20-28 (100 microM) which maximally inhibited PMA-induced insulin secretion, also inhibited the secretory response to CCh, but did not affect glucose-stimulated insulin secretion from intact islets. These results indicate that myristoylation of pseudosubstrate peptides increases their potency as inhibitors and that PKC-myr20-28 is a selective and cell-permeant inhibitor of PMA-sensitive isoforms of PKC. They also suggest that the activation of PMA-sensitive PKC isoforms mediates the stimulatory effects of CCh, but is not obligatory for glucose-induced insulin secretion from pancreatic beta-cells.